Update: HIMSS20 has been canceled due to the coronavirus. Read more here.
While many would agree that healthcare is turning a corner with increasing focus on patient-friendly experiences and the consumerization of healthcare services, not every attempt in this area has been a home run. These shortcomings have been particularly disappointing in the realm of digital, where a successful, well-...
San Francisco-based EHR developer Practice Fusion has agreed to pay $145 million alongside an admission that it “solicited and received kickbacks from a major opioid company” in exchange for clinical decision support (CDS) alerts promoting unnecessary prescription opioids, according to a release from the US Department of Justice.
In a settlement announced yesterday (and hinted at in an earnings...
Unfortunately for us, MobiHealthNews doesn’t have a crystal ball (it would be darn useful for getting scoops). But we do have more than a decade’s worth of experience tracking the emergence of this space and we spend a lot of our time talking to smart people with industry experience and opinions of their own.
As we enter into a new decade in 2020, your MobiHealthNews staff has put our heads...
Update: HIMSS20 has been canceled due to the coronavirus. Read more here.
About the author: Naomi Fried, PhD, is the CEO of Health Innovation Strategies, which provides digital health strategy and innovation-program design and optimization consulting to healthcare stakeholders including pharma, payers and providers. Her previous positions include the first chief innovation officer at Boston...
Editor's note: This story has been updated with information from Verily's announcement of the clearance.
Verily, the life sciences research subsidiary of Alphabet, has received FDA 510(k) clearance for an augmented version of its prescription Study Watch wearable that includes some form of arrhythmia monitoring.
The Study Watch With Irregular Pulse Monitor is classified by the FDA as a “...
Following news of hardships at Proteus Digital Health, CEO Andrew Thompson has told STAT News that the company is winding down its high-profile $88 million deal with Otsuka Pharmaceutical, and will be pivoting from its current primary focus on mental disorders toward cancers and infectious disease treatments.
The pharmaceutical company has now acquired the full license for Proteus’ mental health...
German pharma giant Bayer and British biotech firm Exscientia have announced a three-year partnership focused on the use of Artificial Intelligence in cardiovascular and oncology drug discovery.
The collaboration will initially see the companies work on three early-stage research projects, combining Bayer’s data and drug discovery capabilities and Exscientia’s Centaur Chemist platform.
According...
Editor's note: This story has been updated with additional statements from Pear Therapeutics.
Pear Therapeutics pulled back the curtain this morning on a number of new deals between the prescription digital therapeutics maker and other tech companies or researchers.
Ranging from virtual reality therapies to voice biomarker tech, the moves appear to be an effort from Pear to add new products to...
Stockholm-based respiratory health startup NuvoAir is set to make its technology available in selected cystic fibrosis (CF) centres after entering a new partnership with Roche Italy.
This marks NuvoAir’s first CF deal with a pharma company.
WHY IT MATTERS
According to the UK-based Cystic Fibrosis Trust, the genetic condition is estimated to affect around 100,000 people globally. It causes a...
MobiHealthNews’ parent company HIMSS and Forrester Research announced today a new research partnership that will survey health system leadership on digital health adoption and measure its impact on patient experience and physician burnout. These findings will be presented at March’s HIMSS Global Health Conference & Exhibition in Orlando.
“Uncovering emerging strategies for quantifying...
